Cited 0 times in 
Cited 0 times in 
Integrated amyloid, neurodegeneration, and vascular biomarkers estimate the risk of dementia progression in mild cognitive impairment
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Lee, Woong Jin | - |
| dc.contributor.author | Cho, Kyoungjoo | - |
| dc.contributor.author | Kim, Gyung Whan | - |
| dc.date.accessioned | 2026-06-17T00:48:05Z | - |
| dc.date.available | 2026-06-17T00:48:05Z | - |
| dc.date.created | 2026-06-05 | - |
| dc.date.issued | 2026-05 | - |
| dc.identifier.issn | 1387-2877 | - |
| dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/212617 | - |
| dc.description.abstract | Background: Progression from mild cognitive impairment (MCI) to dementia arises from heterogeneous mechanisms involving Alzheimer's disease (AD) pathology and vascular factors. Objective: This study aimed to develop a multimodal biomarker model to estimate the risk of dementia progression and to examine whether carotid atherosclerosis provides independent prognostic value, particularly in amyloid-beta (A beta)-negative MCI. Methods: We retrospectively analyzed 300 individuals with MCI who underwent baseline [F-18]florbetapir PET, structural MRI, carotid Doppler ultrasound, cognitive assessments, and APOE genotyping (2018-2021). Participants were followed for a total of 37 months to dementia based on longitudinal cognitive and functional decline, independent of follow-up amyloid PET findings. A beta positivity was defined using Brain Amyloid Plaque Load criteria. Multivariable logistic regression and receiver operating characteristic analyses were performed. Results: Among 189 A beta-positive individuals, 30.7% (n = 58) progressed to A beta-positive AD dementia, while 9.0% (n = 10) of 111 A beta-negative individuals developed non-AD dementia. Independent factors estimating A beta-positive AD dementia included higher A beta burden (OR 2.34, p < 0.001), smaller hippocampal volume (OR 0.71, p < 0.001), greater carotid plaque count (OR 1.45, p = 0.001), lower Mini-Mental State Examination (OR 1.11, p = 0.002), and APOE epsilon 4 carriage (OR 1.82, p = 0.021). The integrated model showed excellent performance (AUC 0.903; 95% CI: 0.814-0.968). In A beta-negative MCI, carotid plaque burden was the primary estimator of non-AD dementia progression. Conclusions: The prominent prognostic role of carotid plaques in A beta-negative MCI underscores the vascular contributions to non-amyloid cognitive decline and highlights the importance of evaluating both AD-related and vascular mechanisms in prodromal dementia. | - |
| dc.language | English | - |
| dc.publisher | IOS Press | - |
| dc.relation.isPartOf | JOURNAL OF ALZHEIMERS DISEASE | - |
| dc.relation.isPartOf | JOURNAL OF ALZHEIMERS DISEASE | - |
| dc.title | Integrated amyloid, neurodegeneration, and vascular biomarkers estimate the risk of dementia progression in mild cognitive impairment | - |
| dc.type | Article | - |
| dc.contributor.googleauthor | Lee, Woong Jin | - |
| dc.contributor.googleauthor | Cho, Kyoungjoo | - |
| dc.contributor.googleauthor | Kim, Gyung Whan | - |
| dc.identifier.doi | 10.1177/13872877261445623 | - |
| dc.relation.journalcode | J01231 | - |
| dc.identifier.eissn | 1875-8908 | - |
| dc.identifier.pmid | 42159446 | - |
| dc.identifier.url | https://journals.sagepub.com/doi/10.1177/13872877261445623 | - |
| dc.subject.keyword | Alzheimer&apos | - |
| dc.subject.keyword | s disease | - |
| dc.subject.keyword | amyloid PET | - |
| dc.subject.keyword | APOE epsilon 4 | - |
| dc.subject.keyword | carotid atherosclerosis | - |
| dc.subject.keyword | dementia progression | - |
| dc.subject.keyword | hippocampal atrophy | - |
| dc.subject.keyword | mild cognitive impairment | - |
| dc.subject.keyword | multimodal biomarkers | - |
| dc.subject.keyword | vascular cognitive impairment | - |
| dc.contributor.affiliatedAuthor | Lee, Woong Jin | - |
| dc.contributor.affiliatedAuthor | Kim, Gyung Whan | - |
| dc.identifier.wosid | 001770518400001 | - |
| dc.identifier.bibliographicCitation | JOURNAL OF ALZHEIMERS DISEASE, 2026-05 | - |
| dc.identifier.rimsid | 93242 | - |
| dc.type.rims | ART | - |
| dc.description.journalClass | 1 | - |
| dc.description.journalClass | 1 | - |
| dc.subject.keywordAuthor | Alzheimer&apos | - |
| dc.subject.keywordAuthor | s disease | - |
| dc.subject.keywordAuthor | amyloid PET | - |
| dc.subject.keywordAuthor | APOE epsilon 4 | - |
| dc.subject.keywordAuthor | carotid atherosclerosis | - |
| dc.subject.keywordAuthor | dementia progression | - |
| dc.subject.keywordAuthor | hippocampal atrophy | - |
| dc.subject.keywordAuthor | mild cognitive impairment | - |
| dc.subject.keywordAuthor | multimodal biomarkers | - |
| dc.subject.keywordAuthor | vascular cognitive impairment | - |
| dc.subject.keywordPlus | DISEASE | - |
| dc.type.docType | Article; Early Access | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalWebOfScienceCategory | Neurosciences | - |
| dc.relation.journalResearchArea | Neurosciences & Neurology | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.